| Literature DB >> 34207012 |
Reem Al-Mulla1, Marawan Abu-Madi1,2, Qusai M Talafha2,3, Reema F Tayyem4, Atiyeh M Abdallah1,2.
Abstract
Even though vaccination programs have now started in earnest across the globe and in Qatar, vaccine hesitancy remains a barrier to effectively tackling the pandemic. Many factors influence willingness to take vaccines including safety, efficacy, and side effects. Given their proximity to research and education, university students and employees represent an interesting cohort in which to investigate vaccine hesitancy. The aim of this study was to assess the attitudes of Qatar University employees and students towards the COVID-19 vaccine. In total, 231 employees and 231 students participated in an online cross-sectional study in February 2021. Of the sample, 62.6% were willing to take a vaccine against COVID-19. Participants with or taking postgraduate degrees were more willing to take the vaccine compared to participants with or taking a diploma or bachelor's degree (p < 0.001). Males had a higher rate of vaccine acceptance (p < 0.001). In the group that regarded flu vaccination as important, 13% were unwilling to take COVID-19 vaccine. There were no associations between willingness to vaccinate and vaccine/virus knowledge and social media use. Participants showed a high level of concern regarding vaccine side effects in themselves or their children. Two-thirds agreed or strongly agreed that they would take the vaccine if it was mandatory for international travel. Our participants were neutral to the origin of vaccine development. These findings, which represent data collected after the start of the national vaccination program, show that vaccine hesitancy persists in the Qatari population and that some groups, such as undergraduate students, could benefit from specific, targeted public health campaigns.Entities:
Keywords: COVID-19; Qatar; education sector; hesitancy; post vaccine administration program; vaccine
Year: 2021 PMID: 34207012 PMCID: PMC8235273 DOI: 10.3390/vaccines9060665
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Sociodemographic variables of the study population (n = 462).
| Demographic | Variable Category | n | % |
|---|---|---|---|
| Gender | Male | 173 | 37.4 |
| Female | 289 | 62.6 | |
| Age | 18–24 years | 151 | 32.7 |
| 25–34 years | 117 | 25.3 | |
| 35–44 years | 85 | 18.4 | |
| 45+ years | 109 | 23.6 | |
| Nationality | Qatari | 208 | 45 |
| Non-Qatari | 254 | 55 | |
| University Status | Student | 231 | 50 |
| Employee | 231 | 50 | |
| Colleges | Arts and Sciences | 107 | 23.2 |
| Business and Economics | 76 | 16.5 | |
| Engineering | 66 | 14.3 | |
| Education | 40 | 8.7 | |
| Law | 31 | 6.7 | |
| Health Sciences | 20 | 4.3 | |
| Islamic Studies | 17 | 3.7 | |
| Medicine | 9 | 1.2 | |
| Pharmacy | 6 | 1.3 | |
| Dental Medicine | 1 | 0.2 | |
| Others (including general services and presidency) | 82 | 17.7 | |
| Education Level | Diploma/undergraduate | 270 | 58.4 |
| Postgraduate | 192 | 41.6 |
Figure 1Reasons given for unwillingness to take the COVID-19 vaccine in 170 participants or their children. The y-axis represents % responses. Concern about vaccine safety was a major reason for vaccine hesitancy.
Participant characteristics by COVID-19 vaccine acceptance.
| Demographic | Variable Category | Would Vaccinate | Would Not Vaccinate | X2 | |
|---|---|---|---|---|---|
| Gender | Male | 123 (72.9) | 46 (27.1) | 12.02 | <0.001 |
| Nationality | Qatari | 105 (51.2) | 100 (48.8) | 20.50 | <0.001 |
| Education level | Diplomas/Bachelors | 136 (50.9) | 131 (49.1) | 37.39 | <0.001 |
| Health-related discipline | Health colleges | 29 (80.6) | 7 (19.4) | ||
| Non-health colleges | 255 (61) | 163 (39) | 5.40 | 0.02 |
Relationship between COVID-19 knowledge score and willingness to vaccinate.
| Knowledge Score | Would Vaccinate | Would Not Vaccinate | Statistic | |
|---|---|---|---|---|
| Low (0–3) | 30 (73.2) | 11 (26.8) | X2 = 2.6 | 0.27 |
| Medium (4–5) | 100 (59.5) | 68 (40.5) | ||
| High (6–7) | 154 (62.9) | 91 (37.1) |
Figure 2Attitudes and beliefs toward COVID-19 disease, vaccination, and immunity using a five-point Likert scale.
Relationship between factors and determinants influencing acceptance and willingness to vaccinate.
| Question | Answers | Would Vaccinate | Would Not Vaccinate | Multinomial Logistic Regression Analysis | ||
|---|---|---|---|---|---|---|
| Odd ratio * | 95% CI |
| ||||
| How important is it for you to get the flu vaccine every year? | Important | 93 (86.9) | 14 (13.1) | 8.51 | 4.37–16.5 | <0.0001 |
| Somewhat important | 75 (75.8) | 24 (24.2) | 3.38 | 1.94–5.88 | <0.0001 | |
| Not important | 116 (46.8) | 132 (53.2) | Reference | |||
| What is your primary source of information regarding COVID-19? | Professional source | 139 (65.3) | 74 (34.7) | 2.39 | 0.28–20.1 | 0.43 |
| Unprofessional source | 141 (60) | 94 (40) | 1.81 | 0.21–15.5 | 0.59 | |
| Leaders | 2 (50) | 2 (50) | Reference | |||
| How severe were the symptoms of COVID-19 infection for yourself? | Severe | 1 (16.7) | 5 (9.5) | 0.21 | 0.02–2.01 | 0.17 |
| Moderate | 16 (57.1) | 12 (42.9) | 1.12 | 0.44–2.9 | 0.79 | |
| Not at all | 54 (58.7) | 38 (41.3) | Reference | |||
| How severe were the symptoms of COVID-19 infection for your family member? | Severe | 21 (51.2) | 20 (48.8) | 0.75 | 0.33–1.7 | 0.49 |
| Moderate | 71 (62.3) | 43 (37.7) | 1.21 | 0.65–2.3 | 0.53 | |
| Not at all | 50 (58.8) | 35 (41.2) | Reference | |||
| How severe were the symptoms of COVID-19 infection for your friend? | Severe | 20 (69%) | 9 (31) | 1.39 | 0.54–3.61 | 0.49 |
| Moderate | 77 (57.5) | 57 (42.5) | 0.92 | 0.52–1.62 | 0.77 | |
| Not at all | 57 (58.8) | 40 (41.2) | Reference | |||
| How severe were the symptoms of COVID-19 infection for coworker? | Severe | 6 (50) | 6 50) | 0.10 | 0.08–1.26 | 0.10 |
| Moderate | 54 (62.8) | 32 (37.2) | 0.57 | 0.29–1.16 | 0.12 | |
| Not at all | 64 (66) | 33 (34) | Reference | |||
| What is the minimum length of time a testing process would take to make you feel comfortable with COVID-19 vaccine? | 3 months–1 year | 139 (89.1) | 17 (10.9) | 13.1 | 7.01–24.0 | <0.0001 |
| 1–2 years | 68 (63) | 40 (37) | 2.91 | 1.71–4.91 | <0.0001 | |
| 3+ years | 77 (40.5) | 113 (59.5) | Reference | |||
| I worry that the rushed pace of testing for a COVID-19 vaccine will fail to detect potential side effects. | Agree | 155 (52.9) | 138 (47.1) | 0.26 | 0.12–0.54 | <0.0001 |
| Neither agree nor disagree | 80 (78.4) | 22 (21.6) | 0.75 | 0.32–1.76 | 0.50 | |
| Disagree | 49 (83.1) | 10 (16.9) | Reference | |||
* Odds ratio was adjusted for age, sex, educational level, and nationality (Qatari or non-Qatari).
Figure 3Different levels of vaccine efficacy and participants’ responses on how likely they were to be vaccinated.